Daclatasvir Dihydrochloride | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Daclatasvir Dihydrochloride
HEALTH CANADA PATENTS

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Daclatasvir Dihydrochloride

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

28 API Suppliers, 5 USDMF, 6 EU WC, 5 NDC API, 22 Listed Suppliers, $ API Reference Price

28 API Suppliers
5 USDMF
6 EU WC
5 NDC API
22 Listed Suppliers
$ API Reference Price

INTERMEDIATES

9 Intermediates Suppliers

9 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

12 FDF Dossiers, 3 FDA Orange Book, 6 Europe, 3 Listed Dossiers

12 FDF Dossiers
3 FDA Orange Book
6 Europe
3 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 30MG BASE, TABLET;ORAL - EQ 60MG BASE, TABLET;ORAL - EQ 90MG BASE

TABLET;ORAL - EQ 30MG BASE
TABLET;ORAL - EQ 60MG BASE
TABLET;ORAL - EQ 90MG BASE

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 3 DKSH, 1 Jai Radhe Sales, 7 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Clariant, 10 Corel Pharma Chem, 4 DFE Pharma, 6 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 1 Ingredion Pharma Solutions, 21 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 9 Microlex e.U, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 2 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 10 Roquette, 6 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 9 Sigachi Industries, 2 The Dow Chemical Company, 3 Vasa Pharmachem

1 SPI Pharma
3 DKSH
1 Jai Radhe Sales
7 Gangwal Healthcare
1 Nanjing Well Pharmaceutical
1 ACG Worldwide
6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
1 Clariant
10 Corel Pharma Chem
4 DFE Pharma
6 Gangwal Chemicals
5 Ideal Cures Pvt Ltd
1 Ingredion Pharma Solutions
21 Kerry
3 Kima Chemical
6 Lonza Capsugel
9 Microlex e.U
1 Novo Excipients
1 Pharmatrans-Sanaq
2 Pluviaendo
3 Prachin Chemical
1 Qianhao Chemical (Hebei) Co., Ltd
1 Qualicaps
10 Roquette
6 Seppic
4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
9 Sigachi Industries
2 The Dow Chemical Company
3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

44 Coating Systems & Additives, 31 Fillers, Diluents & Binders, 20 Controlled & Modified Release, 17 Direct Compression, 15 Disintegrants & Superdisintegrants, 13 Thickeners and Stabilizers, 11 Lubricants & Glidants, 10 Granulation, 9 Co-Processed Excipients, 8 Film Formers & Plasticizers, 5 Empty Capsules, 4 Emulsifying Agents, 4 Rheology Modifiers, 4 Vegetarian Capsules, 4 API Stability Enhancers, 4 Taste Masking, 4 Coloring Agents, 3 Chewable & Orodispersible Aids, 2 Topical, 1 Parenteral, 1 Surfactant & Foaming Agents, 1 Solubilizers

44 Coating Systems & Additives
31 Fillers, Diluents & Binders
20 Controlled & Modified Release
17 Direct Compression
15 Disintegrants & Superdisintegrants
13 Thickeners and Stabilizers
11 Lubricants & Glidants
10 Granulation
9 Co-Processed Excipients
8 Film Formers & Plasticizers
5 Empty Capsules
4 Emulsifying Agents
4 Rheology Modifiers
4 Vegetarian Capsules
4 API Stability Enhancers
4 Taste Masking
4 Coloring Agents
3 Chewable & Orodispersible Aids
2 Topical
1 Parenteral
1 Surfactant & Foaming Agents
1 Solubilizers

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow, 44 NEWS #PharmaBuzz

3 DATA COMPILATION #PharmaFlow
44 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

4 Finished Drug Prices, 5 Annual Reports

4 Finished Drug Prices
5 Annual Reports

MARKET PLACE

7 APIs

7 APIs

PATENTS & EXCLUSIVITIES

18 US Patents, 4 Health Canada Patents

18 US Patents
4 Health Canada Patents

$ API Ref.Price (USD/KG) : 654 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

4 All

01 4Bristol-Myers Squibb Canada

filter Patent Reset all filters

4 All

01 22660520

02 22695729

filter Product Reset all filters

4 All

01 4DACLATASVIR DIHYDROCHLORIDE

filter Dosage Reset all filters

4 All

01 4TABLET

filter Exp Date Reset all filters

4 All

01 22027-08-09

02 22028-07-31

Product Main Page

01

Bristol-Myers Squibb Canada

Daclatasvir

2024 ACI Convention

Not Confirmed

Bristol-Myers Squibb Canada

2024 ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-09

Date Granted : 2015-01-13

Daclatasvir

Brand Name : DAKLINZA

Patent Number : 2660520

Filing Date : 2007-08-09

Strength per Unit : 30 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2027-08-09

Date Granted : 2015-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Bristol-Myers Squibb Canada

Daclatasvir

2024 ACI Convention

Not Confirmed

Bristol-Myers Squibb Canada

2024 ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-07-31

Date Granted : 2015-03-31

Daclatasvir

Brand Name : DAKLINZA

Patent Number : 2695729

Filing Date : 2008-07-31

Strength per Unit : 30 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2028-07-31

Date Granted : 2015-03-31

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Bristol-Myers Squibb Canada

Daclatasvir

2024 ACI Convention

Not Confirmed

Bristol-Myers Squibb Canada

2024 ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-07-31

Date Granted : 2015-03-31

Daclatasvir

Brand Name : DAKLINZA

Patent Number : 2695729

Filing Date : 2008-07-31

Strength per Unit : 60 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2028-07-31

Date Granted : 2015-03-31

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Bristol-Myers Squibb Canada

Daclatasvir

2024 ACI Convention

Not Confirmed

Bristol-Myers Squibb Canada

2024 ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-09

Date Granted : 2015-01-13

Daclatasvir

Brand Name : DAKLINZA

Patent Number : 2660520

Filing Date : 2007-08-09

Strength per Unit : 60 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2027-08-09

Date Granted : 2015-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?